|
Jan 31
|
Novartis Pares Gains As Its Bread-And-Butter Drug Faces Looming Competition
|
|
Jan 31
|
Health Care Roundup: Market Talk
|
|
Jan 31
|
Trending tickers: Apple, Intel, Novartis, Shell, Smiths Group
|
|
Jan 31
|
Novartis Expects Further Profit, Sales Growth Despite Competition Threat
|
|
Jan 31
|
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
|
|
Jan 31
|
Chevron earnings, December PCE, FedSpeak: What to Watch
|
|
Dec 31
|
Novartis’ Gene Therapy Shows Promise in Treating SMA
|
|
Dec 30
|
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
|